Form 8-K - Current report:
SEC Accession No. 0001785530-25-000006
Filing Date
2025-03-11
Accepted
2025-03-11 07:05:41
Documents
15
Period of Report
2025-03-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K howl-20250311.htm   iXBRL 8-K 27134
2 EX-99.1 a12312024ex991.htm EX-99.1 70935
6 GRAPHIC werewolflogohorizontalaa.jpg GRAPHIC 277881
  Complete submission text file 0001785530-25-000006.txt   619014

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20250311.xsd EX-101.SCH 1829
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20250311_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20250311_pre.xml EX-101.PRE 13623
17 EXTRACTED XBRL INSTANCE DOCUMENT howl-20250311_htm.xml XML 2919
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 25725833
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)